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Mechanism of Inhibitory Action of AT1 Receptor Blocker and Estrogen on Atherosclerosis
Masahiro Tsuda (Department of Nephrology, Saitama Medical School, Moroyama, Iruma -gun, Saitama, 350 -0495, 
Japan)
　In the present study, we investigated a gender difference of atherosclerotic changes induced in apoE -deficient 
(ApoEKO)mice, focusing on oxidative stress, and the possible interaction between olmesartan, an AT1 (angiotensin 
type 1 receptor)blocker(ARB), and estrogen. After treatment with high cholesterol diet(HCD) for 6 weeks, apparent 
atherosclerotic lesion formation including lipid deposition and increase in superoxide production and p47phox 
expression were observed in ApoEKO mice.  These changes were significantly greater in male than in female mice, 
although plasma cholesterol level was not different. Preceding ovariectomy enhanced atherosclerotic lesion and 
oxidative stress 6 weeks after HCD. The changes in ovariectomized mice were reversed by 17β- estradiol(80μg/
kg/day)replacement. On the other hand, olmesartan(3 mg/kg/day)inhibited both atherosclerosis and oxidative 
stress observed in ApoEKO mice treated with HCD. The inhibitory effect of olmesartan on atherosclerosis was 
significantly stronger in female than in male and ovariectomized ApoEKO mice. Neither the smaller dose of 
estrogen(20μg/kg/day)nor olmesartan(0.5 mg/kg/day)influenced atherosclerosis and oxidative stress. However, 
co - administration of olmesartan and estrogen at these smaller doses attenuated atherosclerosis as well as 
oxidative stress.  We further investigated interaction between AT1 receptor stimulation and estrogen on NADPH 
oxidase activity using cultured VSMC, which mainly was expressed AT1 receptor.  The NADPH oxidase activity 
in cultured VSMC was increased by Angiotensin II. 17β- estradiol attenuated NADPH oxidase activity induced by 
angiotensin II without affecting the expression of AT1 receptor.  These results indicate that estrogen enhances the 
inhibitory effect of AT1 receptor blocker on atherosclerosis. Our results also suggest that estrogen and ARB act 
synergistically to inhibit oxidative stress, by attenuating NADPH oxidase activity.
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Oriental Yeast Co. Ltd.）あるいは高コレステロール食 
（1.25％ cholesterol, 10％ coconut oil in MF） で6週間
飼育した．両側卵巣摘出は高コレステロール食開始
48時間前に施行した．17β -estradiol （Sigma Chemial 
Co., St. Louis, MO）（20 あるいは 80μg/kg/day）は
propylene glycolで溶解し皮下投与した．ARBである
Olmesartan （RNH-6270, 三共株式会社より供与）は
osmotic minipump （Alzet model 1002, DURECT 
Corporation, Cuper tino, CA） を用いて0.5あるいは
3.0 mg/kg/dayの用量で腹腔内投与した 16)．血中
コレステロール値はcholesterol oxidase法（Cholesterol 
E-test, WAKO Chemical Industries, Ltd., Tokyo）を
用いて，組織Ang IIはPeninsula Laboratories Kit 





Densitograph Imaging Software（ATTO Corporation, 










摘出し，氷冷したTris - surcrose buffer（10 mM Tris 
pH 7.1, 340 mM surcrose, 1 mM EDTA, 1 mM PMSF, 
10μg/mL aprotinin）500 mLでホモジナイズし，30分
間抽出した．さらにサンプルを遠心（15,000 g, 10 min, 
4℃）し， 上清（20μg protein）に78μM cytochrome C 
（Sigma -Aldrich, St. Louis, MO）, 100μM NADPH 







を行ったのち，定量的polymerase chain reactionをSYBR 
green I キット（MJ Research, Inc., Waltham, MA） を用い
て行った．
PCRプライマーは，
p47phox : 5’ -GTCCCTGCATCCTATCTGGA-3’（forward） 
5 ’ -GGGACATCTCGTCCTCTTCA -3 ’（reverse）,
AT1受容体: 5’ -GTTCCTGCTCACGTGTCTCA-3’（forward） 
5 ’ -CATCAGCCAGATGATGATGC -3 ’（reverse）, 





今回の実験では 5から 7継代したsubconfluent VSMCを
用いた．AT1やAT2のreceptor binding はHayashidaらの
報告に従い測定した 21)．すなわち，1μmol/L valsartan 
あるいは 1μmol/L PD123319（Research Biochemical 
International）存在，非存在下で 125I - [Sar1, Ile8] Ang II








した後，培養液とAng II （Sigma Chemical Co., St. Louis, 
MO） ，17β - estradiol （Sigma Chemical Co.）を添加
した．NADPH oxidase活性は 5μmol/L の lucigeninを
用いて測定した 5)．化学発光は luminometer （AB-2200, 












（雄性マウス 対照群 : 46±3.6 mg/dL, 比較群 : 1684±
96.0 mg/dL, 雌性マウス 対照群: 46.6±3.6 mg/dL, 比較



















群 : 1536±65 mg/dL, エストロゲン投与群 : 1557±57 
mg/dL）．また，卵巣摘出及びエストロゲン投与は血
圧には影響を与えず（対照群 : 118.6±6.1 mmHg, 卵巣
摘出群 : 111.2±3.9 mmHg, エストロゲン投与群 : 112.1
±6.8 mmHg ），組織Ang IIについても，卵巣摘出とエ
ストロゲン投与共に正常雌性マウスと同レベルであっ
た（雌性マウス : 59±5.0 pg/mg protein, 卵巣摘出群 : 57
±7.0 pg/mg protein, エストロゲン投与群（80μg/kg/













Fig. 1. Sex dif ference in atherosclerotic area and ef fect 
of olmesartan in apolipoprotein -deficient (ApoEKO) mice. 
ApoEKO mice were treated with a high -cholesterol diet or 
standard normal diet for 6 weeks as described in “Materials 
and Methods”. Olmesartan was administered at a dose of 0.5 
or 3 mg/kg/day for 2 weeks before sampling. Aortic samples 
were taken and cross sections were prepared as described in 
“Methods”. (A) Representative results of oil red -O staining 
of proximal aorta.  Magnification x 200. (B) Morphometric 
analysis of atherosclerotic area and lipid area in cross sections 
of proximal aorta.  Values are mean±SE of 7 - 8 experiments. 
*p＜0.05 vs. HCD. ND: standard normal diet, HCD: high -
cholesterol diet, Olm: olmesartan, (a～d) male mice, (e～h) 
female mice. a and e: ND, b and f: HCD, c and g: olmesartan 





ス 対照群 : 114.5±4.2 mmHg, olmesartan投与群 : 114.6
±1.6 mmHg, 雌性マウス 対照群 : 118.6±6.1 mmHg, 
olmesartan投与群 : 115.7±9.2 mmHg, 卵巣摘出群 併用
投与群 : 117.1±6.3 mmHg），血中コレステロール値に
も影響を与えなかった （olmesartan投与群 : 1628±98 














NADPH oxidase活性とp47 phox mRNAレベルの上昇が
有意に抑制された（Fig. 4, 5, 6A）．一方，3 mg/kg/day
のolmesartanはsuperoxide産生，NADPH oxidase活性
とp47 phox mRNA発現を抑制したが，この抑制効果は雌
Fig. 2. Effect of estrogen and olmesartan on atherosclerotic 
area in ovariectomized ApoEKO mice. Female ApoEKO mice 
were ovariectomized and treated with HCD as described in 
“Methods”. 17β - estradiol was administered at a dose of 20 
or 80μg/kg/day for 14 days before sampling. Olmesartan 
was administered at a dose of 0.5 or 3.0 mg/kg/day 14 days 
before sampling. Aortic samples were taken as described 
in Figure 1. (A) Representative results of oil red -O staining 
of proximal aorta.  Magnification x 200. (B) Morphometric 
analysis of atherosclerotic area and lipid area in cross sections 
of proximal aorta. Values are mean±SE of 7 - 8 experiments. 
†p＜0.05 vs .  HCD, **p＜0.01 vs .  HCD＋OVX. OVX: 
ovariectomy, Olm: olmesartan, E: 17β - estradiol. a: control 
(OVX mice), b: olmesartan (0.5 mg/kg/day), c: olmesartan 
(3.0 mg/kg/day), d: 17β- estradiol (20μg/kg/day), e: 
17β - estradiol (80μg/kg/day), f: olmesartan (0.5 mg/kg/
day) and 17β- estradiol (20μg/kg/day).
Fig. 3. Sex difference on superoxide production in ApoEKO 
mice. Freshly frozen sections of proximal aor ta were 
prepared and superoxide was detected with dihydroethidium 
as described in “Materials and Methods”.  Olmesartan and 
17β- estradiol were administered as described in Figure 
2.  (a～d) male mice, (e～h) female mice. a and e: ND, b 
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性マウスでより強く認められた （Fig. 3, 5, 6A）．特に，
比較的低用量のolmesartan （0.5 mg/kg/day）は，雄性
マウスや卵巣摘出マウスにおけるsuperoxide産生，
NADPH oxidase活性，p47 phox mRNA発現上昇に影響
を与えなかったが，雌性マウスにおいては，明らかに
これらの変化を抑制した （Fig. 4, 5, 6A）．比較的低用
量の17β - estradiol （20μg/kg/day）とolmesartan （0.5 
mg/kg/day） は，単独では上記の変化に影響を及ぼさ
なかったが，これら両者を併用すると，superoxide産
生，NADPH oxidase活性，p47 phox mRNA発現が有意









　Fig. 7に示すように，Ang IIはVSMCにおけるNADPH 
oxidase活性上昇を引き起こした （15分後にピーク）．
17β- estradiol （10-8 M）単独ではNADPH oxidaseに影












17β- estradiol投与により回復した （Fig. 2）．今回用い
た17β- estradiol投与量で，卵巣摘出により，血中エ
ストロゲン濃度の著しい低下を認め （対照群 : 224.6±






Fig. 4. Effect of olmesartan and estrogen on superoxide 
production in ovariectomized ApoEKO mice. Superoxide was 
detected with dihydroethidium as described in “Materials and 
Methods”. Olmesartan and 17β - estradiol were administered 
as described in Figure 2. a: control (OVX mice), b: olmesartan 
(0.5 mg/kg/day), c: olmesar tan (3.0 mg/kg/day), d: 
17β - estradiol (20μg/kg/day), e: 17β - estradiol (80μg/
kg/day), f: olmesartan (0.5 mg/kg/day) and 17β - estradiol 
(20μg/kg/day).
Fig. 5. Effect of olmesartan and estrogen on NADPH oxidase 
activity in ApoEKO mice. Protein samples were prepared 
and NADPH oxidase activity was measured as described in 
“Methods”. Olmesartan and 17β - estradiol were administered 
as described in Figure 2. Values are mean±SE of 7 - 8 
experimemts. *p＜0.05 vs. ND, †p＜0.05 vs. HCD, **p＜






ず （雄性マウス: 1684±96 mg/dL, 雌性マウス : 1592±79 
mg/dL），エストロゲンやolmesartanによる影響は認め
なかったので脂質代謝以外の作用が関与していると考
える （エストロゲン投与群 : 1557±57 mg/dL, olmesartan









改善することを明らかにした （Fig. 3, 4, 5, 6A）．
　Superoxide産生とNADPH oxidaseの活性化は動脈硬











17β- estradiolがAT1受容体由来のextracellular signal -
Fig. 7. Ef fect of estrogen on NADPH oxidase activity 
induced by Ang II in cultured VSMC.  Subconfluent VSMC 
were incubated with Ang II (10-7 M) and 17β - estradiol (10-8 
M) for 0, 5, 15, 30 minutes, and 1, 3, 6, 12, 24 hours. NADPH 
oxidase activity was measured by the chemiluminescence 
method using lucigenin as described in “Methods”. Values are 
expressed as mean±SE of 4 experiments. ○ : Ang II (10-7 M), 
△: 17β - estradiol (10-8 M), ●: Ang II with 17β - estradiol.
Fig. 6. Effect of olmesartan and estrogen on expression of 
p47phox and AT1 receptor in ApoEKO mice. Aortic samples 
were taken from ApoEKO mice as described in Figure 1. 
Levels of p47phox mRNA and AT1 receptor mRNA were assayed 
by quantitative real time RT -PCR as described in “Methods”. 
(A) Ef fect of combination of olmesartan and estrogen on 
expression of p47phox mRNA in ApoEKO mice. (B) Effect of 
combination of olmesartan and estrogen on expression of AT1 
receptor mRNA in ApoEKO mice.  Values are mean±SE of 5 
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性マウスで強く認められ （Fig. 1, 2, 3, 4, 5, 6A），卵巣
摘出マウスにおいては，比較的低用量のolmesartanと
17β- estradiolの併用により脂肪沈着，動脈硬化性病
変，superoxide産生，NADPH oxidase活性とp47 phox 












































レステロールの酸化 46)，macrophage chemoattractant 

























































1. apolipoprotein E遺伝子欠損 （ApoEKO） マウスの
おける動脈硬化形成に対し，エストロゲン及び
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